Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven solid tumour for which CPT-11 given by the Folfiri regimen is indicated and prescribed by the attending physician.~* Age above 21 years.~* Measurable or evaluable disease~* Karnofsky performance status \> 70%~* Life expectancy \> 3 months~* WBC \> 3.0 x 103/?l; ANC \> 1500/?l~* Hemoglobin \> 9.0 g/dl~* Platelets \> 100000/?l~* Creatinine \< 1.5 x ULN or calculated creatinine clearance \> 40 ml/min~* Total bilirubin \< 1.5 x ULN~* SGOT, SGPT \< 5 x ULN unless due to disease~Exclusion Criteria:~* Biologic therapy or chemotherapy within 4 weeks. (Six weeks for prior nitrosoureas or mitomycin C).~* Radiation therapy within 4 weeks if \> 25% of bone marrow was irradiated.~* Have not received any medications that are known to be metabolised by UGT1A1 within 30 days of the first dose of CPT-11.~* Short gut syndrome or other causes of malabsorption.~* Colony stimulating factors within 2 weeks.~* Women of childbearing potential not practicing birth control. (Note: by means other than oral contraception)~* Pregnant women~* Severe peripheral neuropathy grade 2 or higher.~* Medical or psychiatric conditions which may impair the patient's ability to provide informed consent.~* Hypersensitivity to CPT-11, raltegravir or midazolam/other benzodiazepines.~* Rapidly progressive intracranial or spinal metastatic disease.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPT-11 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).